This product is a humanized (from mouse) IgG1, κ antibody that can recognize human CD22.
Figure 1 Incidence of >10% of all treatment-emergent AEs in patients receiving single-agent pinatuzumab vedotin (2.4 mg/kg): iNHL versus DLBCL.
Most AEs reported in the 39 NHL patients treated at the RP2D (2.4 mg/kg) were grade 1–2 in severity. Twenty-seven (69%) patients reported grade 3–4 adverse events; the most common in ≥2 patients included neutropenia, fatigue, peripheral sensory neuropathy, hyperglycemia, and anemia. Grade 3 febrile neutropenia was reported in one patient. Serious AEs were reported in 13 (33%) NHL patients. Pyrexia was reported in 3 patients and dyspnea in 2 patients; otherwise, no single serious AE was reported in ≥2 patients. Thirteen (33%) patients discontinued pinatuzumab vedotin treatment due to an AE.
Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., ... & Agarwal, P. (2017). Phase I study of the anti-CD22 antibody–drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 23(5), 1167-1176.
Figure 2 Tumor reductions were mostly observed at pinatuzumab vedotin doses ≥1.8 mg/kg.
Observed antitumor responses in DLBCL patients (A) and iNHL patients (B). Dashed lines indicate 50% increases and 50% decreases in SPD from baseline. R, refractory; SPD, sum of the product of the diameters.
Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., ... & Agarwal, P. (2017). Phase I study of the anti-CD22 antibody–drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 23(5), 1167-1176.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1248z-F(E) | Recombinant Anti-Human CD22 Antibody Fab Fragment | IP, RIA, FuncS | Fab |
HPAB-0194-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0194-LSX-F(E)) | ELISA | Mouse Fab |
HPAB-0195-LSX-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0195-LSX-F(E)) | ELISA | Human Fab |
HPAB-0196-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0196-LSX-F(E)) | ELISA | Mouse Fab |
HPAB-0197-LSX-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0197-LSX-F(E)) | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-176 | Anti-Human CD22 Recombinant Antibody (Epratuzumab) | IF, IP, Neut, FuncS, ELISA, FC, ICC | IgG1 |
TAB-1725CL-S(P) | Human Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1725CL-S(P)) | Block, Cyt, ELISA, FuncS | Humanized scFv |
TAB-1729CL-S(P) | Human Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1729CL-S(P)) | IF, FC | Humanized scFv |
TAB-002LC-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (VM1000) | ELISA, SPR | Humanized antibody |
TAB-002LC-F(E) | Anti-Human CD22 Recombinant Antibody Fab Fragment (VM1000) | ELISA, SPR | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-183-F(E) | Anti-Human CD22 Recombinant Antibody (Moxetumomab Pasudotox) | FuncS, IF, Neut, ELISA, FC, IP, ICC | Fv - disulfide stabilized |
TAB-1714CL-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1714CL-S(P)) | ELISA, WB | Mouse scFv |
TAB-1723CL-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1723CL-S(P)) | Inhib | Mouse scFv |
TAB-1728CL-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (RFB4) | IF, FC | |
TAB-1714CL-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1714CL-F(E)) | ELISA, WB | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L048E | anti-CD22 immunotoxin RFB4 (scFv)-PE | Cytotoxicity assay, Functional assay | |
AGTO-L048D | anti-CD22 immunotoxin RFB4 (scFv)-DT | Cytotoxicity assay, Functional assay | |
AGTO-L048G | anti-CD22 immunotoxin RFB4 (scFv)-Gel | Cytotoxicity assay, Functional assay | |
AGTO-L048R | anti-CD22 immunotoxin RFB4 (scFv)-RTA | Cytotoxicity assay, Functional assay | |
AGTO-L048S | anti-CD22 immunotoxin RFB4 (scFv)-Sap | Cytotoxicity assay, Functional assay |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0196CL | Anti-Human CD22 Recombinant Antibody (hLL2) | Inhib, Cyt, FC, WB | |
TAB-0197CL | Anti-Human CD22 Recombinant Antibody (hLL2-Cys) | ELISA, In vivo | |
TAB-1721CL-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (CD22.1) | ELISA, FC, FuncS | Human antibody |
TAB-1721CL-F(E) | Anti-Human CD22 Recombinant Antibody Fab Fragment (CD22.1) | ELISA, FC, FuncS | Human antibody |
TAB-1722CL-F(E) | Anti-Human CD22 Recombinant Antibody Fab Fragment (CD22.2) | ELISA, FC, FuncS | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1724CL | Human Anti-CD22 Recombinant Antibody (TAB-1724CL) | Inhib | Chimeric (mouse/human) IgG1, κ |
TAB-1724CL-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1724CL-F(E)) | Inhib | Chimeric (mouse/human) Fab |
TAB-001LC | Human Anti-CD22 Recombinant Antibody (TAB-001LC) | ELISA | Chimeric antibody (mouse/human) |
TAB-001LC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-001LC-S(P)) | ELISA | Mouse scFv |
TAB-001LC-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-001LC-F(E)) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-001LC | Recombinant Anti-Human CD22 Antibody (Fab glycosylation) | ELISA, FC | Mouse antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-111LC | Recombinant Anti-Human CD22 Antibody (Fc glycosylation) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-315CQ | Rat Anti-CD22 Recombinant Antibody (clone 2D6) | Block | Rat IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0545 | Hi-Affi™ Rabbit Anti-CD22 Recombinant Antibody (clone DS545AB) | IP, WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0195-LSX | Human Anti-CD22 Recombinant Antibody (HPAB-0195-LSX) | Apop, Cyt, FC, WB, Inhib, FuncS, IF, ELISA | Human IgG |
HPAB-0196-LSX | Mouse Anti-CD22 Recombinant Antibody (HPAB-0196-LSX) | ELISA, FC, IP, RIA | Mouse IgG |
HPAB-0197-LSX | Human Anti-CD22 Recombinant Antibody (HPAB-0197-LSX) | ELISA, FC, FuncS | Human IgG |
HPAB-0198-LSX | Mouse Anti-CD22 Recombinant Antibody (HPAB-0198-LSX) | ELISA, WB, IF, FC, SPR | Mouse IgG |
HPAB-0199-LSX | Human Anti-CD22 Recombinant Antibody (HPAB-0199-LSX) | ELISA, FC | Human IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-N0324-YC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-N0324-YC-S(P)) | FuncS | Mouse scFv |
HPAB-N0325-YC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-N0325-YC-S(P)) | FuncS | Mouse scFv |
HPAB-0370-FY-S(P) | Human Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-0370-FY-S(P)) | ELISA | Humanized scFv |
HPAB-0371-FY-S(P) | Human Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-0371-FY-S(P)) | Inhib | Humanized scFv |
HPAB-2052-FY-S(P) | Human Anti-CD22 Recombinant Antibody (clone B28); scFv Fragment | FC | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-176 | Afuco™ Anti-CD22 ADCC Recombinant Antibody (Epratuzumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-198 | Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-899. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.